Triple-drug colorectal cancer review reports survival alongside substantial toxicity
Pooled survival results describe patients receiving encorafenib, cetuximab, and binimetinib, but do not quantify improvement over another treatment.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
This review summarizes outcomes among patients receiving a specific triple-drug treatment for a defined colorectal cancer mutation. Survival and tumor responses were reported, alongside substantial toxicity. Because the abstract presents pooled treated-patient outcomes without a comparative treatment estimate, it does not establish how much the combination improves survival over another option.
The included studies used different designs, and the survival estimate was imprecise. The abstract does not provide a pooled comparison against another treatment.
What researchers found
Pooled overall survival rate
At 12 months among patients receiving triple therapy; no comparator estimate reported in the abstract.
What survival means here
The survival result is a pooled estimate for treated patients at a specified time. It does not measure added survival from treatment, and it does not predict an individual patient's outcome.
Adverse events were common
Grade ≥3 adverse events were reported in 46% of patients. Acne-like skin inflammation and diarrhea were the most common reported events in this category, showing the treatment burden alongside the survival findings.
The original publication
Safety and Efficacy of Triple Therapy Containing Encorafenib, Cetuximab, and Binimetinib for BRAF V600E-Mutated Colorectal Cancer: a Systematic Review and Meta-Analysis.
Ansab M, Ramzan NUH, Ishaque G et al.
J Gastrointest Cancer · 2026
- PubMed ID
- 41677963
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.